Clinical importance of antiplatelet drugs in cardiovascular diseases

Clinical Hemorheology and Microcirculation

Volumn 53, Issue 1-2, 2013, Pages 81-96

  Papp, J ^a   Kenyeres, P ^a   Toth, K ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antiplatelet drugs; aspirin and clopidogrel resistance; coronary heart disease; inhibition of platelet aggregation; peripheral arterial disease; platelet aggregometry; stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; DICLOFENAC; DIPYRONE; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; IBUPROFEN; LEFRADAFIBAN; LOTRAFIBAN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORBOFIBAN; PARACETAMOL; PRASUGREL; ROFECOXIB; ROXIFIBAN; SIBRAFIBAN; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; XEMILOFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LOW DRUG DOSE; NEUTROPENIA; PATHOPHYSIOLOGY; RISK ASSESSMENT; SKIN DISEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE;

ACUTE CORONARY SYNDROME; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE;

EID: 84872931171     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-2012-1578     Document Type: Article

References (73)

1. H.P. Adams Jr, G. del Zoppo, M.J. Alberts, et al., Guidelines for the Early Management of Adults with Ischemic Stroke: Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists, Stroke 38 (2007), 1655-1711.
2. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya,T.A. Bass and M.A. Costa,Variability in individual responsiveness to Clopidogrel, Am J Cardiol 103 (2009), 27A-34A.
3. Antithrombotic Trialists' Collaboration, C. Baigent, L. Blackwell, et al., Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials, Lancet 373 (2009), 1849.
4. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ 324 (2002), 71-86.
5. D. Antoniucci, Differences among GP IIb/IIIa inhibitors: Different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients, Eur Heart J Suppl 9 (2007), A32-A36.
6. D. Aradi, A. Komocsi, A. Vorobcsuk, O. Rideg, M. Tokes-Fuzesi, T. Magyarlaki, I.G. Horvath and V.L. Serebruany, Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis, Am Heart J 160 (2010), 543-551.
7. A. Aszodi, A. Pfeifer,M. Ahmad, M. Glauner, X.H. Zhou, L. Ny, K.E. Andersson, B. Kehrel, S. Offermanns and R. Fassler, The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonistinduced platelet aggregation, but is dispensable for smooth muscle function, EMBO J 18 (1999), 37-48.
8. D.L. Bhatt, Aspirin resistance: More than just a laboratory curiosity, J Am Coll Cardiol 43 (2004), 1127-1129.
9. D.L. Bhatt, B.L. Cryer, C.F. Contant, M. Cohen, A. Lanas, T.J. Schnitzer, T.L. Shook, P. Lapuerta, M.A. Goldsmith, L. Laine, B.M. Scirica, S.A. Murphy and C.P. Cannon, Clopidogrel with or without omeprazole in coronary artery disease, N Engl J Med 363 (2010), 1909-1917.
10. D.L. Bhatt, K.A. Fox,W. Hacke, et al., Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med 354 (2006), 1706-1717.
11. K. Broos, S.F. De Meyer, H.B. Feys, K. Vanhoorelbeke and H. Deckmyn, Blood platelet biochemistry, Thromb Res 129 (2012), 245-249.
12. C.P. Cannon, R.A. Harrington, S. James, et al., for the PLATelet inhibition and patient Outcomes (PLATO) investigators: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study, Lancet 375 (2010), 283-293.
13. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet 348 (1996), 1329.
14. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, S.N. Vyas and G.A. FitzGerald, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med 345 (2001), 1809-1817.
15. M. Cattaneo, New P2Y12 inhibitors, Circulation 121 (2010), 171-179.
16. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, R. Peto, R. Collins and L.S. Liu, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial, Lancet 366 (2005), 1607-1621.
17. M.I. Chimowitz, M.J. Lynn, C.P. Derdeyn, et al., Stenting versus aggressive medical therapy for intracranial arterial stenosis, N Engl J Med 365 (2011), 993-1003.
18. CURE Trial Investigators, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, New Engl J Med 345 (2001), 494-502.
19. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, M. Kaste, D. Leys, J. Matias-Guiu and H.J. Rupprecht, MATCH investigators, Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial, Lancet 364 (2004), 331-337.
20. P.P. Dobesh, Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor, Pharmacotherapy 9 (2009), 1089-1102.
21. J.W. Eikelboom, J. Hirsh, J.I.Weitz, M. Johnston, Q. Yi and S. Yusuf, Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation 105 (2002), 1650-1655.
22. G. Feher, A. Feher, G. Pusch, K. Koltai, A. Tibold, B. Gasztonyi, E. Papp, L. Szapary, G. Kesmarky and K. Toth, Clinical importance of aspirin and clopidogrel resistance, World J Cardiol 26 (2010), 171-186.
23. G. Feher, K. Koltai, G. Kesmarky and K. Toth, Hemorheological background of acetylsalicylic acid resistance, Clin Hemorheol Microcirc 38 (2008), 143-152.
24. R. Fitzgerald and M. Pirmohamed, Aspirin resistance: Effect of clinical, biochemical and genetic factors, Pharmacol Ther 130 (2011), 213-225.
25. K.L. Furie, S.E. Kasner, R.J. Adams, et al., Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the american heart association/american stroke association, Stroke 42 (2011), 227-276.
26. L.A. Garcia Rodriguez, C. Varas and C. Patrono, Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women, Epidemiology 11 (2000), 382-387.
27. L.A. Garcia Rodriguez, C. Varas-Lorenzo, A. Maguire and A. Gonzalez-Perez, Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population, Circulation 109 (2004), 3000-3006.
28. B.J. Gersh, B.J. Maron, R.O. Bonow, et al., A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, J Am Coll Cardiol 58 (2011), e212-260.
29. T. Goodman, A. Ferro and P. Sharma, Pharmacogenetics of aspirin resistance: A comprehensive systematic review, Br J Clin Pharmacol 66 (2008), 222-232.
30. P.A. Gurbel, K.P. Bliden, K. Butler, M.J. Antonino, C.Wei, R. Teng, L. Rasmussen, R.F. Storey, T. Nielsen, J.W. Eikelboom, G. Sabe-Affaki, S. Husted, D.J. Kereiakes, D. Henderson, D.V. Patel and U.S. Tantry, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: TheRESPONDstudy, Circulation 121 (2010), 1188-1199.
31. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, C. Wei, R. Teng, M.J. Antonino, S.B. Patil, A. Karunakaran, D.J. Kereiakes, C. Parris, D. Purdy, V. Wilson, G.S. Ledley and R.F. Storey, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study, Circulation 120 (2009), 2577-2585.
32. P.A. Gurbel, D.J. Kereiakes and U.S. Tantry, Ticagrelor for the treatment of arterial thrombosis, Expert Opin Pharmacother 11 (2010), 2251-2259.
33. P.A. Gurbel and V.L. Serebruany, Oral platelet IIb/IIIa inhibitors: From attractive theory to clinical failures, J Thromb Thrombolysis 10 (2000), 217-220.
34. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber,M. Ohman, M.C. Petrie, F. Sonntag, M.U. Sousa, R.F. Storey, W. Vijns and D. Zahger, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur Heart J 32 (2011), 2999-3054.
35. L.A. Harker and R.A. Kadatz, Mechanism of action of dipyridamole, Thromb Res 4(Suppl 1) (1983), 39-46.
36. W.K. Hass, J.D. Easton, H.P. Adams Jr, W. Pryse-Phillips, B.A. Molony, S. Anderson and B. Kamm, A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group, N Engl J Med 321 (1989), 501-507.
37. J. Hippisley-Cox and C. Coupland, Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis, BMJ 330 (2005), 1366.
38. D.R. Holmes Jr, D.J. Kereiakes, N.S. Kleiman, D.J. Moliterno, G. Patti and C.L. Grines, Combining antiplatelet and anticoagulant therapies, J Am Coll Cardiol 54 (2009), 95-109.
39. P.A. Howard and P. Delafontaine, Nonsteroidal anti-inflammatory drugs and cardiovascular risk, J Am Coll Cardiol 43 (2004), 519-525.
40. Y. Huang, Y. Cheng, J.Wu, et al., Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study, Lancet Neurol 7 (2008), 494-499.
41. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, O. Barthelemy, G. Cayla, F. Beygui and G. Montalescot, Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. A systematic meta-analysis, J Am Coll Cardiol 56 (2010), 134-143.
42. K. Kaushansky, Regulation of megakaryopoiesis, in: J. Loscalzo, A.I. Schafer: Thrombosis and Hemorrhage, William & Wilkins, Baltimore, 1998, 173-193.
43. W. Korte, M. Cattaneo, P.G. Chassot, S. Eichinger, C. von Heymann, N. Hofmann, H. Rickli, M. Spannagl, B. Ziegler, F. Verheugt and K. Huber, Peri-operative management of antiplatelet therapy in patients with coronary artery disease, Thromb Haemost 105 (2011), 743-749.
44. G. Krasopoulos, S.J. Brister, W.S. Beattie and M.R. Buchanan, Aspirin "resistance" and risk of cardiovascular morbidity: A systematic review and meta-analysis, BMJ 336 (2008), 195-198.
45. M.G. Lansberg, M.J. O'Donnell, P. Khatri, E.S. Lang, M.N. Nguyen-Huynh, N.E. Schwartz, F.A. Sonnenberg, S. Schulman, P.O. Vandvik, F.A. Spencer, P. Alonso-Coello, G.H. Guyatt and E.A. Akl, American College of Chest Physicians, Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest 141 (2012), e601S-636S.
46. F.W. Leebeek, E. Boersma, C.P. Cannon, F.J. van deWerf and M.L. Simoons, Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: Why were the results so unfavourable, Eur Heart J 23 (2002), 444-457.
47. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, I. Goldenberg, I. Novikov, H. Pres, N. Savion, D. Varon and H. Hod, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation 109 (2004), 3171-3175.
48. M. Matsumoto, Cilostazol in secondary prevention of stroke: Impact of the cilostazol stroke prevention study, Atheroscler Suppl 6 (2005), 33-40.
49. S.R. Mehta, J.P. Bassand, S. Chrolavicius, R. Diaz, J.W. Eikelboom, K.A. Fox, C.B. Granger, S. Jolly, C.D. Joyner, H.J. Rupprecht, P. Widimsky, R. Afzal, J. Pogue and S. Yusuf, CURRENT-OASIS 7 Investigators, Dose comparisons of clopidogrel and aspirin in acute coronary syndromes, N Engl J Med 363 (2010), 930-942.
50. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, K. Malmberg, H. Rupprecht, F. Zhao, S. Chrolavicius, I. Copland and K.A. Fox, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study, Lancet 358 (2001), 527-533.
51. A.D. Michelson, Antiplatelet therapies for the treatment of cardiovascular disease, Nat Rev Drug Discov 9 (2010), 154-169.
52. J. Miner and A. Hoffhines, The discovery of Aspirin's antithrombotic effects, Tex Heart Inst J 34 (2007), 179-186.
53. S. Moncada and J.R. Vanee, Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin, Pharmacol Rev 30 (1979), 293-331.
54. J.J. Nawarskas and S.M. Clark, Ticagrelor: A novel reversible oral antiplatelet agent, Cardiol Rev 19 (2011), 95-100.
55. C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, S.D. Kristensen, J. Morais, F.J. Neumann, L.H. Rasmussen, A. Siegbahn, P.G. Steg, R.F. Storey, F. Van de Werf and F. Verheugt, Antiplatelet agents for the treatment and prevention of atherothrombosis, Eur Heart J 32 (2011), 2922-2932.
56. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh and G. Roth, Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 126 (2004), 234S-264S.
57. G. Patti, G. Colonna, V. Pasceri, L.L. Pepe, A. Montinaro and G. Di Sciascio, Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study, Circulation 111 (2005), 2099-2106.
58. W.A. Ray, C.M. Stein, K. Hall, J.R. Daugherty and M.R. Griffin, Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study, Lancet 359 (2002), 118-123.
59. P. Robless, D.P. Mikhailidis and G.P. Stansby, Cilostazol for peripheral arterial disease, Cochrane Database Syst Rev 1 (2007), CD003748.
60. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, P. Theroux, M.J. Claeys, F. Cools, K.A. Hill, A.M. Skene, C.H. McCabe and E. Braunwald, CLARITY-TIMI 28 Investigators, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med 352 (2005), 1179-1189.
61. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, P. Theroux, B.S. Lewis, S.A. Murphy, C.H. McCabe and E. Braunwald, Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients withST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study, JAMA294 (2005), 1224-1232.
62. W.M. Samara, K.P. Bliden, U.S. Tantry and P.A. Gurbel, The difference between clopidogrel responsiveness and posttreatment platelet reactivity, Thromb Res 115 (2005), 89-94.
63. F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, G. Davi and C. Patrono, Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays, J Am Coll Cardiol 53 (2009), 667-677.
64. D. Scheinichen, H.A. Elsner, R. Osorio, B. J?uttner, W. Groschel, K. Jaeger and S. Piepenbrock, Lack of influence of the COX inhibitors metamizol and diclofenac on platelet GPIIb/IIIa and P-selectin expression in vitro, BMC Anesthesiol 4 (2004), 4.
65. K. Schror, The pharmacology of cilostazol, Diabetes Obes Metab 2(Suppl 2) (2002), S14-19.
66. S.R.K. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, S. Erqou, N. Sattar and K.K. Ray, Effect of aspirin on vascular and nonvascular outcomes, Arch Intern Med 172 (2012), 209-216.
67. Steering, Committee, of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study, N Engl J Med 321 (1989), 129-135.
68. S.R. Steinhubl, P.B. Berger, J.T. Mann 3rd, E.T. Fry, A. DeLago, A., C. Wilmer and E.J. Topol, CREDO Investigators, Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial, JAMA 288 (2002), 2411-2420.
69. F. Van deWerf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P.G. Steg, M. Tubaro, F. Verheugt, F. Weidinger and M. Weis, ESC Committee for Practice Guidelines (CPG), The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology, Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation, Eur Heart J 29 (2008), 2909-2945.
70. C. Verstuyft, T. Simon and R.B. Kim, Personalized medicine and antiplatelet therapy: Ready for prime time? Eur Heart J 30 (2009), 1943-1963.
71. D. Vivas and D.J. Angiolillo, Platelet P2Y12 receptor inhibition: An update on clinical drug development, Am J Cardiovasc Drugs 10 (2010), 217-226.
72. S.D. Wiviott, E. Braunwald, CH McCabe, et al., TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med 357 (2007), 2001-2015.
73. S.D. Wiviott, M.D. Flather, M.L. O'Donoghue, S. Goto, D.J. Fitzgerald, F. Cura, P. Aylward, V. Guetta, D. Dudek, C.F. Contant, D.J. Angiolillo and D.L. Bhatt, LANCELOT-CAD Investigators Randomized trial of atopaxar in the treatment of patients with coronary artery disease: The lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial, Circulation 123 (2011), 1854-1863.